COVID-19 Vaccines Resources

By AHRMM

When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus.

This webpage is intended to help keep the supply chain field informed of important updates related to the progress and distribution of COVID-19 vaccines. Resources and information will be added and updated often as new developments occur.

<< Return to AHRMM's COVID-19 page.

AHA COVID-19 Vaccines and Therapeutics

When the novel coronavirus (SARS-CoV-2) emerged in late 2019, hundreds of individuals and organizations around the world quickly mobilized to develop a vaccine for COVID-19, the disease caused by the virus. As the virus surged in 2020, therapeutics were developed to treat those with COVID-19 in outpatient and inpatient settings. This webpage is intended to help keep the field informed of important updates related to the progress and distribution of COVID-19 vaccines, along with in-development therapeutics for patients with COVID-19.

CDC COVID-19 Vaccination Program Interim Playbook

This playbook serves as an interim playbook for state, territorial, tribal and local public health programs and their partners on how to plan and operationalize a vaccination response to COVID-19 within their jurisdictions.

 

Pfizer and BioNTech COVID-19 Vaccine Approval

On August 23, 2021, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

Moderna COVID-19 Vaccine

As of January 31, 2022, the U.S. Food and Drug Administration approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for the prevention of COVID-19 in individuals 18 years of age and older. 

Johnson & Johnson-Janssen COVID-19 Vaccine

The Johnson & Johnson-Janssen COVID‑19 Vaccine is for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The vaccine contains a recombinant, replication-incompetent human adenovirus serotype 26 (Ad26) vector, encoding the SARS-CoV-2 viral spike (S) glycoprotein, stabilized in its pre-fusion form. It is an investigational vaccine not licensed for any indication.

COVID-19 Boosters

On October 20, Today, the U.S. Food and Drug Administration took action to expand the use of a booster dose for COVID-19 vaccines in eligible populations. The agency is amending the emergency use authorizations (EUA) for COVID-19 vaccines to allow for the use of a single booster dose.

COVID-19 Boosters

On Decemeber 22, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Related Resources

Toolkits/Methodology
A collection of links to websites on the coronavirus (COVID-19) outbreak, including FDA's Emergency Use Authorizations, CDC's resources, testing…
On-Demand Educational Webinars
The AHRMM Learning Community held its first open forum on March 27 to discuss the health care supply chain's latest response to COVID-19. Moderated…
Toolkits/Methodology
AHRMM offers definitions and guidance on health care masks, including mask types and efficacies, fit testing guidelines, distributor information and…
Resources
AHRMM is collaborating with a valued third-party company utilizing their solution, expertise and processes to vet non-traditional suppliers offering…
Resources
AHRMM is keeping members and the public up to date on the latest Novel Coronavirus (COVID-19) developments with links to guidance from AHA, CDC, and…